Stocks
Amylyx Pharmaceuticals Financial Statements (AMLX) |
||||||||||
| Amylyx Pharmaceuticalssmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 31.12.2019 | 31.12.2020 | 31.03.2022 | 13.03.2023 | 22.02.2024 | 07.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 1.43 | 0.650 | 0.285 | 22.2 | 380.8 | 198.5 | |||
| Operating Income, bln rub | -13.6 | -39.0 | -82.7 | -201.3 | 38.8 | -249.3 | ||||
| EBITDA, bln rub | ? | 1.11 | -39.0 | -82.6 | -200.9 | 39.9 | -212.0 | |||
| Net profit, bln rub | ? | -14.8 | -44.8 | -87.9 | -198.4 | 49.3 | -259.5 | |||
| OCF, bln rub | ? | -10.7 | -36.7 | -74.8 | -179.9 | 11.9 | -95.1 | |||
| CAPEX, bln rub | ? | 0.000 | 0.151 | 0.353 | 2.53 | 1.24 | 0.531 | |||
| FCF, bln rub | ? | -10.7 | -36.8 | -75.2 | -182.4 | 10.7 | -95.6 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | ||||||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 13.6 | 39.0 | 82.7 | 220.6 | 316.5 | 311.3 | ||||
| Cost of production, bln rub | 11.9 | 24.6 | 0.052 | 2.99 | 25.4 | 134.5 | ||||
| R&D, bln rub | 11.9 | 24.6 | 44.0 | 93.5 | 128.2 | 125.6 | ||||
| Interest expenses, bln rub | 1.28 | 2.29 | 0.000 | 4.29 | 0.000 | 3.46 | ||||
| Assets, bln rub | 3.22 | 14.1 | 105.6 | 391.5 | 517.5 | 250.7 | ||||
| Net Assets, bln rub | ? | -25.4 | -66.7 | -151.2 | 340.6 | 433.4 | 196.2 | |||
| Debt, bln rub | 14.9 | 1.43 | 0.000 | 6.28 | 4.24 | 2.57 | ||||
| Cash, bln rub | 3.09 | 12.9 | 96.1 | 346.9 | 371.4 | 234.4 | ||||
| Net debt, bln rub | 11.8 | -11.5 | -96.1 | -340.7 | -367.1 | -231.8 | ||||
| Ordinary share price, rub | 37.0 | 14.7 | ||||||||
| Number of ordinary shares, mln | 56.5 | 56.5 | 57.9 | 66.5 | 67.2 | 68.1 | ||||
| Market cap, bln rub | 0 | 0 | 0 | 2 458 | 990 | 0 | ||||
| EV, bln rub | ? | 12 | -11 | -96 | 2 117 | 623 | -232 | |||
| Book value, bln rub | -25 | -67 | -151 | 341 | 433 | 196 | ||||
| EPS, rub | ? | -0.26 | -0.79 | -1.52 | -2.98 | 0.73 | -3.81 | |||
| FCF/share, rub | -0.19 | -0.65 | -1.30 | -2.74 | 0.16 | -1.40 | ||||
| BV/share, rub | -0.45 | -1.18 | -2.61 | 5.12 | 6.45 | 2.88 | ||||
| EBITDA margin, % | ? | 78.1% | -6 001% | -28 995% | -903.5% | 10.5% | -106.8% | |||
| Net margin, % | ? | -1 039% | -6 898% | -30 835% | -892.4% | 12.9% | -130.7% | |||
| FCF yield, % | ? | -7.42% | 1.08% | |||||||
| ROE, % | ? | 58.4% | 67.2% | 58.1% | -58.2% | 11.4% | -132.2% | |||
| ROA, % | ? | -460.1% | -317.9% | -83.2% | -50.7% | 9.52% | -103.5% | |||
| P/E | ? | 0.00 | 0.00 | 0.00 | -12.4 | 20.1 | 0 | |||
| P/FCF | 0.00 | 0.00 | 0.00 | -13.5 | 92.7 | 0 | ||||
| P/S | ? | 0.00 | 0.00 | 0.00 | 110.6 | 2.60 | 0 | |||
| P/BV | ? | 0.00 | 0.00 | 0.00 | 7.22 | 2.28 | 0 | |||
| EV/EBITDA | ? | 10.6 | 0.29 | 1.16 | -10.5 | 15.6 | 1.09 | |||
| Debt/EBITDA | 10.6 | 0.29 | 1.16 | 1.70 | -9.20 | 1.09 | ||||
| R&D/CAPEX, % | 16 287% | 12 476% | 3 700% | 10 329% | 23 650% | |||||
| CAPEX/Revenue, % | 0.00% | 23.2% | 123.9% | 11.4% | 0.33% | 0.27% | ||||
| Amylyx Pharmaceuticals shareholders | ||||||||||
